ANABIOTICASubmit a source Weight loss.
Weight-management evidence includes intensive lifestyle treatment, approved medicines, and surgery. The strongest results come from defined populations receiving structured follow-up; they do not make every option appropriate for every person.
10 evidence-ranked entriesWhat the evidence cannot settle yet
Average trial results can hide differences in eligibility, dose, adherence, discontinuation, maintenance, and access to ongoing care. Investigational toplines and short follow-up cannot substitute for completed pivotal trials or long-term outcome data.
Risks depend on the intervention
Gastrointestinal effects, contraindications, pregnancy precautions, medicine interactions, and monitoring needs vary by treatment. Surgery adds procedure-specific risks and lifelong nutritional follow-up, while prescription therapies require clinical oversight.
Strong evidence leads this category
Ratings compare confidence in each entry's stated benefit—not whether every intervention is appropriate or recommended.
How ratings workEvery weight loss entry
Sorted from stronger to weaker evidence.
Semaglutide
A prescription GLP-1 medicine with strong trial evidence for substantial weight loss in eligible adults when combined with lifestyle support.
Tirzepatide
A prescription GIP/GLP-1 medicine that produced substantial, sustained weight loss in a large phase 3 obesity trial.
Metabolic and Bariatric Surgery
The most durable established treatment for severe obesity, with large weight and metabolic benefits alongside procedure-specific lifelong risks and follow-up.
Liraglutide
A daily GLP-1 receptor agonist with strong obesity-trial evidence for clinically meaningful weight loss, balanced against gastrointestinal effects, cost, and regain after stopping.
Orlistat
An oral intestinal lipase inhibitor that produces modest, durable weight loss but commonly causes meal-dependent gastrointestinal effects.
Phentermine + Topiramate
An effective once-daily oral obesity medicine whose weight-loss benefit must be balanced against pregnancy, cognitive, mood, and cardiovascular precautions.
Intensive Lifestyle Intervention
A high-contact program of calorie reduction, physical activity, behavioral skills, and long-term support that can sustain meaningful weight loss without guaranteeing cardiovascular-event reduction.
Naltrexone + Bupropion
An oral prescription combination that produces modest average weight loss but has important opioid, seizure, blood-pressure, and psychiatric precautions.
Setmelanotide
A daily MC4-receptor agonist for specific rare genetic and acquired hypothalamic obesity—not a general obesity drug.
Retatrutide
An investigational triple-hormone-receptor agonist with unusually large phase 2 weight-loss results and promising but not yet peer-reviewed phase 3 toplines.